Transparency Market Research in its new report titled, “Myocarditis Disease Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the myocarditis disease market. The TMR report anticipates that the entry of novel, highly priced therapies and high unmet needs will boost the myocarditis disease market during the forecast period i.e, 2018-2026.
According to the report, there are several unmet needs in global myocarditis disease market, which create significant opportunities for existing players and new entrants in the global market. Recombint Peptides, vaccines and small molecule provide ample opportunities for players operating in the global myocarditis disease market. Recent ongoing developments in myocarditis disease drugs such as Evotec AG LAB282, CEL-SCI’s CEL-1000, Swedish Orphan Biovitrum AB uncovers the potential of these drugs. Competitive activity is increasing as larger companies realize the rewards of investing in orphan therapeutics. High unmet needs and low competition in several regions is expected to attract more companies to the market in the near future. The clinical studies for the molecules receiving the funding from the U.S. government for the rare disease lead to increase in development of molecules.
The report has segregated the global myocarditis disease market based on drug type, dosage form, molecule type and geography. On the basis of drug type, myocarditis disease market is split into antibiotics, anti-inflammatory diuretics and branded drugs. Treatment is to reduce swelling and remove excess water from the body. In terms of dosage form, the injectable form segment led the market, in terms of revenue, in 2017. The segment is projected to maintain its dominant position in the market during the forecast period. In terms of molecule type, small molecule was the leading segment of the market in 2017. It is likely to hold a leading share of the market during the forecast period. On a geographical standpoint, North America held a major share of the myocarditis disease therapeutics market in 2017. Increasing prevalence of myocarditis disease among infants and the rise in awareness about the effect of the infection are likely to drive the market in North America. The market in Europe and Asia Pacific is projected to gain market share during the forecast period and is likely to account for a significant share of the market, in terms of revenue, in the near future. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and financial support for research and development for antiviral drugs in countries such as Brazil, South Africa, etc. are likely to boost the market in Latin America and Middle East and Africa.
Some of the major companies operating in the global myocarditis disease market are profiled in this report to give a better competitive analysis and these include CEL-SCI Corp, Evotec AG, Swedish Orphan Biovitrum AB, ARMO Biosciences and Novartis. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
